| Immune thrombocytopenic purpura
Gammaked vs Alvaiz
Side-by-side clinical, coverage, and cost comparison for immune thrombocytopenic purpura.Deep comparison between: Gammaked vs Alvaiz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAlvaiz has a higher rate of injection site reactions vs Gammaked based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Alvaiz but not Gammaked, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gammaked
Alvaiz
At A Glance
IV infusion
Immune globulin
Oral
Daily
TPO-receptor agonist
Indications
- Primary immune deficiency disorder
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Immune thrombocytopenic purpura
- Hepatitis C, Chronic
- Severe Aplastic Anemia
Dosing
Primary immune deficiency disorder IV: 300-600 mg/kg every 3-4 weeks; SC (PI only): individualized weekly dose calculated as previous IGIV dose (g) x 1.37 divided by number of weeks between IV doses.
Immune thrombocytopenic purpura IV only: total dose 2 g/kg given as 1 g/kg on two consecutive days or 0.4 g/kg on five consecutive days; do not administer subcutaneously.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating IV only: loading dose 2 g/kg over two to four consecutive days; maintenance 1 g/kg every 3 weeks (or 0.5 g/kg on two consecutive days every 3 weeks).
Immune thrombocytopenic purpura Initiate at 36 mg orally once daily (18 mg for East-/Southeast-Asian ancestry or hepatic impairment; 9 mg for both); adjust in 18-mg increments to maintain platelet count >=50 x 10^9/L; maximum 54 mg daily.
Hepatitis C, Chronic Initiate at 18 mg orally once daily; adjust in 18-mg increments every 2 weeks to achieve platelet count needed to initiate or maintain pegylated interferon and ribavirin therapy; maximum 72 mg daily; discontinue when antiviral therapy is discontinued.
Severe Aplastic Anemia Initiate at 36 mg orally once daily (18 mg for East-/Southeast-Asian ancestry or hepatic impairment); adjust in 36-mg increments every 2 weeks to maintain platelet count >=50 x 10^9/L; maximum 108 mg daily.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity reaction
—
Adverse Reactions
Most common (>=5%) PI (IV): cough, rhinitis, pharyngitis, headache, asthma, nausea, fever, diarrhea, sinusitis; PI (SC): local infusion site reactions, fatigue, headache, upper respiratory tract infection, arthralgia, diarrhea, nausea, sinusitis, bronchitis, depression, allergic dermatitis, erythema, migraine, myalgia, viral infection, pyrexia; ITP: headache, ecchymosis, vomiting, fever, nausea, rash, abdominal pain, back pain, dyspepsia; CIDP: headache, pyrexia, hypertension, chills, rash, nausea, arthralgia, asthenia
Serious Pulmonary embolism (CIDP), exacerbation of autoimmune pure red cell aplasia (PI), hemolytic anemia
Postmarketing Anaphylaxis, tachycardia, acute renal dysfunction/failure, ARDS, TRALI, pulmonary edema, cardiac arrest, thromboembolism, coma, seizures, aseptic meningitis, Stevens-Johnson syndrome, pancytopenia, hemolytic anemia, hepatic dysfunction
Most common (>=3%) Nausea, diarrhea, upper respiratory tract infection, vomiting, urinary tract infection, increased ALT, myalgia, oropharyngeal pain, increased AST, pharyngitis, back pain, influenza, paresthesia, rash
Serious Hemorrhage, thrombotic/thromboembolic complications, hepatic decompensation, hepatotoxicity, cataracts
Postmarketing Skin discoloration including hyperpigmentation and skin yellowing
Pharmacology
GAMMAKED is an immune globulin that supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins; the precise mechanism of action in ITP and CIDP has not been fully elucidated.
Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (cMpl), initiating signaling cascades that induce proliferation and differentiation of megakaryocytes, leading to increased platelet production.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gammaked
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Alvaiz
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (1/12)
UnitedHealthcare
Gammaked
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Alvaiz
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Gammaked
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Alvaiz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Gammaked.
Cost estimate not availablePAF Co-Pay Relief: Aplastic Anemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GammakedView full Gammaked profile
AlvaizView full Alvaiz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.